{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:11:32Z","timestamp":1784826692081,"version":"3.55.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, highlighting an urgent need for non-invasive early biomarkers. The cholesterol, high-density lipoprotein, and glucose index (CHG) is a novel composite marker reflecting disturbances in glucose and lipid metabolism. However, the independent association between CHG and MASLD, and the potential statistical mediating effect of visceral adiposity, as represented by the body roundness index (BRI), remains unclear, especially in non-diabetic individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 13,682 non-diabetic Japanese adults. Multivariable logistic regression, generalized additive models, and two-piecewise linear regression were used to explore the association, nonlinear relationship, and threshold effect between CHG and MASLD. Receiver operating characteristic (ROC) curve analysis was performed to evaluate CHG\u2019s discriminatory performance. Exploratory mediation analysis was performed to statistically decompose the association between CHG and MASLD via BRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of MASLD was 15.25%. After full adjustment, each 1-unit increase in CHG was independently associated with a higher risk of MASLD (OR\u202f=\u202f4.46, 95% CI: 3.00\u20136.64). A significant dose\u2013response trend was observed across CHG quartiles (Q4 vs. Q1: OR\u202f=\u202f4.09, 95% CI: 2.83\u20135.91). A nonlinear threshold effect was identified at CHG\u202f=\u202f5.52. CHG showed excellent discriminatory performance (AUC\u202f=\u202f0.84), with an optimal cutoff at 5.23 (sensitivity\u202f=\u202f0.81, specificity\u202f=\u202f0.73), and retained robust discriminatory capacity in non-obese and young individuals. BRI showed a significant statistical mediating effect in the CHG\u2013MASLD association, accounting for 46.15% of the total observed association. Subgroup mediation analyses revealed that this mediating effect was more pronounced in non-obese and normotriglyceridemic individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In non-diabetic Japanese adults, CHG is independently and nonlinearly associated with MASLD risk, with BRI as a potential statistical mediator. This mediating effect exhibits heterogeneity and is more pronounced in non-obese individuals. The causal direction of this pathway remains to be verified in prospective studies. CHG shows potential as a low-cost indicator for early MASLD risk stratification, especially in non-obese and younger populations who are often missed by conventional screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1868410","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:40:43Z","timestamp":1784824843000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory mediation analysis of body roundness index in the nonlinear association between CHG index and metabolic dysfunction-associated steatotic liver disease among non-diabetic adults"],"prefix":"10.3389","volume":"13","author":[{"given":"Yanyan","family":"Xuan","sequence":"first","affiliation":[{"name":"Department of Hospital Infection, The First Affiliated Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"Department of Hepatology, The First Affiliated Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"Department of Geriatrics Medicine, The First Affiliated Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics Medicine, The First Affiliated Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Geriatrics Medicine, The First Affiliated Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e70342","DOI":"10.1111\/liv.70342","article-title":"Two-decade trends in MASLD and its complications in the Middle East and North Africa (2010-2021)","volume":"45","author":"Younossi","year":"2025","journal-title":"Liver Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: a review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ueg2.70072","article-title":"The rising global burden of MASLD and other metabolic diseases (2000-2021)","volume":"13","author":"Danpanichkul","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"101271","DOI":"10.1016\/j.jhepr.2024.101271","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021","volume":"7","author":"Feng","year":"2025","journal-title":"JHEP Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"156549","DOI":"10.1016\/j.metabol.2026.156549","article-title":"Rising burden of MASLD and CKM syndrome in Asia: a decade of trends and future projections","volume":"178","author":"Duo","year":"2026","journal-title":"Metabolism"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/jgh.70080","article-title":"Epidemiology of metabolic dysfunction-associated Steatotic liver disease in south Asian ethnicities: A systematic review and Meta-analysis","volume":"40","author":"James","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/s0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e2516367","DOI":"10.1001\/jamanetworkopen.2025.16367","article-title":"Projected trends in metabolic dysfunction-associated Steatotic liver disease mortality through 2040","volume":"8","author":"Zhang","year":"2025","journal-title":"JAMA Netw Open"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","article-title":"Impact of non-invasive biomarkers on hepatology practice: past, present and future","volume":"76","author":"Anstee","year":"2022","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","article-title":"The Asian Pacific Association for the Study of the liver: clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease","volume":"19","author":"Eslam","year":"2025","journal-title":"Hepatol Int"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/hep.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of non-alcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/JS9.0000000000003576","article-title":"Decoding the triglyceride-glucose index in metabolic dysfunction-associated steatotic liver disease: integrative insights from Mendelian randomization, cross-tissue transcriptomics, and spatial multi-omics","volume":"112","author":"Wei","year":"2026","journal-title":"Inter J Surg"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12933-024-02572-w","article-title":"Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK biobank","volume":"24","author":"Qiao","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s13098-025-02069-w","article-title":"Personalized MASLD and liver fibrosis risk assessment for adults: glycemic status determines optimal choice of non-invasive indices","volume":"17","author":"Zhao","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/EJE-17-0883","article-title":"METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes","volume":"178","author":"Bello-Chavolla","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/jdi.14343","article-title":"A novel index for diagnosis of type 2 diabetes mellitus: cholesterol, high density lipoprotein, and glucose (CHG) index","volume":"16","author":"Mansoori","year":"2025","journal-title":"J Diabet Invest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1665074","DOI":"10.3389\/fendo.2026.1665074","article-title":"Investigating the prediction potential of cholesterol, high-density lipoprotein, and glucose index surpasses TyG, AIP, and METS-IR for type 2 diabetes: a longitudinal cohort study","volume":"17","author":"Chen","year":"2026","journal-title":"Front Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-026-03104-4","article-title":"The cholesterol, high-density lipoprotein, and glucose (CHG) index as a novel metabolic marker for predicting adverse outcomes in myocardial infarction survivors: insights from two large prospective cohorts","volume":"25","author":"Song","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1725495","DOI":"10.3389\/fnut.2025.1725495","article-title":"Association between the CHG index and cardiometabolic multimorbidity: a nationwide prospective cohort and multi-community cross-sectional study","volume":"12","author":"Liu","year":"2025","journal-title":"Front Nutr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1365-2362.2003.01263.x","article-title":"Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins","volume":"33","author":"Borggreve","year":"2003","journal-title":"Eur J Clin Investig"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","article-title":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"400","author":"Iturbe-Rey","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"101109","DOI":"10.1016\/j.plipres.2021.101109","article-title":"Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis","volume":"83","author":"Li","year":"2021","journal-title":"Prog Lipid Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1771118","DOI":"10.3389\/fendo.2026.1771118","article-title":"Associations of cholesterol, high-density lipoprotein, and glucose index and triglyceride-glucose-related indices with carotid atherosclerosis in young and middle-aged individuals","volume":"17","author":"Du","year":"2026","journal-title":"Front Endocrinol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12933-025-02675-y","article-title":"Cholesterol, high-density lipoprotein, and glucose index versus triglyceride-glucose index in predicting cardiovascular disease risk: a cohort study","volume":"24","author":"Mo","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1782215","DOI":"10.3389\/fmed.2026.1782215","article-title":"Association of the total cholesterol-high-density lipoprotein-glucose index with metabolic-associated steatotic liver disease: a 5-year retrospective cohort study","volume":"13","author":"Liu","year":"2026","journal-title":"Front Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12933-026-03079-2","article-title":"Association of cholesterol, high-density lipoprotein, and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts","volume":"25","author":"Zhu","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/oby.20408","article-title":"Relationships between body roundness with body fat, and visceral adipose tissue emerging from a new geometrical model","volume":"21","author":"Thomas","year":"2013","journal-title":"Obesity"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.5152\/tjg.2023.23101","article-title":"Comparison of obesity-related indicators for non-alcoholic fatty liver disease diagnosed by transient Elastography","volume":"34","author":"Tian","year":"2023","journal-title":"Turk J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.1111\/dom.16601","article-title":"Body roundness index (BRI) and obesity-related anthropometrics: relationship to visceral adiposity, insulin sensitivity index, and cardiometabolic risk","volume":"27","author":"Eng","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"15442","DOI":"10.1038\/s41598-025-99540-5","article-title":"Nonlinear association between body roundness index and metabolic dysfunction-associated steatotic liver disease in non-diabetic Japanese adults","volume":"15","author":"Huang","year":"2025","journal-title":"Sci Rep"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1604398","DOI":"10.3389\/fnut.2025.1604398","article-title":"Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999-2018","volume":"12","author":"Yi","year":"2025","journal-title":"Front Nutr"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-025-02544-3","article-title":"Effectiveness of body roundness index for the prediction of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"24","author":"Khanmohammadi","year":"2025","journal-title":"Lipids Health Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12944-025-02714-3","article-title":"Exploring the U-shaped nonlinear relationship of CHG index with metabolic syndrome and mortality risks in metabolic syndrome patients","volume":"24","author":"Wei","year":"2025","journal-title":"Lipids Health Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-41569-1","article-title":"Cholesterol-high-density lipoprotein-glucose index versus triglyceride-glucose-derived indices for predicting 10-year cardiovascular mortality in the MASHAD cohort","volume":"16","author":"Tajik","year":"2026","journal-title":"Sci Rep"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1682279","DOI":"10.3389\/fendo.2025.1682279","article-title":"Total cholesterol, high-density lipoprotein, and glucose (CHG) index and diabetic retinopathy in middle-aged and elderly Chinese adults with diabetes: a cross-sectional study","volume":"16","author":"Cao","year":"2025","journal-title":"Front Endocrinol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/dom.70338","article-title":"Association of cumulative exposure to cholesterol, high-density lipoprotein, and glucose index with the risk of cardiovascular disease and all-cause mortality: A longitudinal cohort study","volume":"28","author":"Tian","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12933-026-03081-8","article-title":"Association of cumulative cholesterol-HDL-glucose index with blood pressure changes and risk of new-onset hypertension in middle-aged and older adults: a cohort study","volume":"25","author":"Zhang","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1664891","DOI":"10.3389\/fneur.2025.1664891","article-title":"A comparative analysis of the cholesterol-high-density lipoprotein-glucose index and the triglyceride-glucose index in predicting in-hospital mortality in critically ill ischemic stroke patients","volume":"16","author":"Luwen","year":"2025","journal-title":"Front Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1686931","DOI":"10.3389\/fendo.2025.1686931","article-title":"The role of three glucose\/lipid composite indices (CHG, TYG, and AIP) in predicting carotid plaque and fatty liver outcomes: a retrospective cohort study","volume":"16","author":"Li","year":"2025","journal-title":"Front Endocrinol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1757164","DOI":"10.3389\/fnut.2026.1757164","article-title":"Evaluation of the CHG index for identifying metabolic dysfunction-associated steatotic liver disease: evidence from two independent Asian non-obese populations","volume":"13","author":"Chen","year":"2026","journal-title":"Front Nutr"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13102376","article-title":"Adipose tissue insulin resistance: A key driver of metabolic syndrome pathogenesis","volume":"13","author":"Rabiee","year":"2025","journal-title":"Biomedicine"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"9818","DOI":"10.3390\/ijms24129818","article-title":"Molecular mechanisms for the vicious cycle between insulin resistance and the inflammatory response in obesity","volume":"24","author":"Szukiewicz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of non-alcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in non-alcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13121486","article-title":"Targeting insulin resistance, reactive oxygen species, inflammation, programmed cell death, ER stress, and mitochondrial dysfunction for the therapeutic prevention of free fatty acid-induced vascular endothelial lipotoxicity","volume":"13","author":"Khoi","year":"2024","journal-title":"Antioxidants"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/joim.12540","article-title":"Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis, and novel lipids","volume":"280","author":"Smith","year":"2016","journal-title":"J Intern Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s13679-023-00519-y","article-title":"The role of tumor necrosis factor-alpha in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"12","author":"Vachliotis","year":"2023","journal-title":"Curr Obes Rep"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/hep.22350","article-title":"Visceral fat: a key mediator of steatohepatitis in metabolic liver disease","volume":"48","author":"van der Poorten","year":"2008","journal-title":"Hepatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1161\/CIRCULATIONAHA.112.000682","article-title":"Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis","volume":"127","author":"Ganda","year":"2013","journal-title":"Circulation"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nm1785","article-title":"Hepatic insulin resistance directly promotes formation of cholesterol gallstones","volume":"14","author":"Biddinger","year":"2008","journal-title":"Nat Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jhep.2022.03.017","article-title":"Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis","volume":"77","author":"Beaulant","year":"2022","journal-title":"J Hepatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199715","article-title":"Obesity-driven metabolic disorders: the interplay of inflammation and mitochondrial dysfunction","volume":"26","author":"Choi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15050287","article-title":"From childhood obesity to metabolically dysfunctional-associated steatotic liver disease (MASLD) and hyperlipidemia through oxidative stress during childhood","volume":"15","author":"Accacha","year":"2025","journal-title":"Meta"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1868410\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:40:44Z","timestamp":1784824844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1868410\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":62,"alternative-id":["10.3389\/fnut.2026.1868410"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1868410","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1868410"}}